McKesson's oncology and multispecialty business added $3.6 billion of revenue in three months. That specialty-pharma surge helped push total sales up 7.7%, to $105.4 billion, and lifted operating income 27.3%.
The odd part is what happened below that line: net income fell 21.7% to $614 million, and diluted earnings per share dropped to $5.15 from $6.25. McKesson grew the business and improved its operating margin, but shareholders got less reported profit.
The strongest growth came from the higher-margin-sounding corner of a famously low-margin business, though the filing does not provide enough detail to connect that mix shift to the consolidated earnings decline. Management says the Oncology & Multispecialty increase came from higher specialty pharmaceutical sales in provider solutions.
"2025 Oncology & Multispecialty revenues for the three months ended June 30, 2026 increased $3.6 billion or 33% compared to the same prior year period primarily driven by higher specialty pharmaceutical sales in provider solutions."
McKesson 10-Q, Aug. 5, 2026
That is a substantial contribution to a distributor's growth, not merely a rounding error. North American Pharmaceutical sales also rose, with McKesson citing higher volumes from institutional healthcare providers and retail national account customers, partly offset by branded-drug price decreases and conversions to generics.
The operating improvement was real but narrow. Gross margin moved from 3.4% to 3.5%, while operating margin rose from 1.1% to 1.3%. McKesson says fluctuations in its tax rate reflect the mix of earnings across jurisdictions and discrete tax items, leaving the precise bridge from higher operating income to lower net income unresolved.
There were also unusual corporate items in the period. McKesson disclosed a $34 million credit tied to its estimated opioid-claims liability, alongside $23 million of charges related to the planned separation of Medical-Surgical Solutions and higher restructuring charges.
"Corporate expenses, net decreased for the three months ended June 30, 2026 compared to the same prior year period primarily due to a $34 million credit related to our estimated liability for opioid-related claims as discussed in more detail in Financial Note 11, 'Commitments and Contingent Liabilities,' offset by $23 million of charges related to our planned separation of the Medical-Surgical Solutions Segment, and higher restructuring charges."
McKesson 10-Q, Aug. 5, 2026
The balance sheet adds another wrinkle. Operating cash flow improved from negative $918 million to negative $220 million, while cash rose from $2.4 billion to $5.2 billion. Working capital increased, primarily because receivables rose with higher sales and timing, and inventory reached $26.3 billion, up 4.8% from a year earlier.
That cash figure is not operating cash generation, and the distinction matters for a distributor that moves enormous dollar volumes on thin margins. Capital spending was essentially flat at $112 million, so the period's cash-flow improvement did not come from a major cut to investment.
The company's annual results show the same operating shape in miniature: fiscal 2026 revenue reached $403.4 billion, while operating margin was 1.5% and net margin was 1.2%. More sales can produce better operating leverage, but tax items, separation costs, restructuring, and working-capital timing still decide what reaches the bottom line.
McKesson's next three-month report will give the cleanest comparison in its reported operating cash flow, currently negative $220 million, alongside whether net income reconnects with the stronger operating result.
Source: McKesson's 10-Q for the three months ended June 30, 2026, filed Aug. 5, 2026.